P
Paulo Lúcio
Researcher at Instituto Português de Oncologia Francisco Gentil
Publications - 5
Citations - 116
Paulo Lúcio is an academic researcher from Instituto Português de Oncologia Francisco Gentil. The author has contributed to research in topics: Multiple myeloma & Chronic lymphocytic leukemia. The author has an hindex of 3, co-authored 5 publications receiving 106 citations. Previous affiliations of Paulo Lúcio include Nova Southeastern University.
Papers
More filters
Journal ArticleDOI
Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia
Leila R. Martins,Paulo Lúcio,Alice Melão,I Antunes,Bruno A. Cardoso,R Stansfield,Maria Teresa Sabrina Bertilaccio,Paolo Ghia,D Drygin,Maria Gomes da Silva,João T. Barata +10 more
TL;DR: Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia is inhibited by a second substance called CK2A, which is cytotoxic to lymphocytes and excites the immune system to attack these cells.
Journal ArticleDOI
Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor
Leila R. Martins,Yasser Perera,Paulo Lúcio,Maria Gomes da Silva,Silvio E. Perea,João T. Barata +5 more
TL;DR: It is shown that CIGB-300 promotes activation of the tumor suppressor PTEN and abrogates PI3K-mediated downstream signaling in CLL cells, and provides pre-clinical support for the testing and possible inclusion of CK2 inhibitors in the clinical arsenal against CLL.
Journal ArticleDOI
Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
Cristina João,José Alexandre Freitas,F. J. Gomes,Catarina Geraldes,Inês Coelho,Manuel Neves,Paulo Lúcio,Susana Esteves,Graça Esteves +8 more
TL;DR: LenDex dose adjustment, according to these principles, does not negatively impact response and improves treatment tolerance, has a clear potential to treat this group of patients and to induce long duration of responses.
Journal ArticleDOI
Characterization of Circulating and Bone Marrow Derived Exosomes in Multiple Myeloma Patients
TL;DR: The positive correlation of the exosomal protein cargo in PB and BM samples may be a reflection of the BM compartment and potentially supports the use of EXO as liquid biopsies for biomarkers of BM disease, in a less invasive method.
Journal ArticleDOI
Multiple myeloma patients-derived exosomes as a potential new clinical tool
TL;DR: The positive correlation of the number of exosomes in PB and BM samples in MM and MGUS patients may support the use of EXO as liquid biopsies for biomarkers of BM disease, as a less invasive method.